BMJ reports that a federal judge in New York has ruled that the Food and Drug Administration cannot restrict off-label marketing information for an approved drug so long as the information is truthful and not misleading. The judgment was based on the First Amendment—the right to free speech.
The post Court rules that FDA cannot restrict off-label marketing appeared first on Corporations and Health.